Figure 1.
Treatment with rAd-p53 or oxaliplatin alone inhibits the growth of gastric cancer cells in a time- and dose-dependent manner. SGC-7910 (A), BGC-823 (B) and HGC-27 (C) cells were treated with rAd-p53 followed by the determination of cell growth inhibition rates. Groups A, B, C and D were treated with the indicated rAd-p53 dose (vp/mL) of 5 × 106, 5 × 107, 5 × 108 and 5 × 109, respectively. SGC-7910 (D), BGC-823 (E) and HGC-27 (F) cells were treated with oxaliplatin (OXA), and cell growth inhibition rates were determined. Groups a, b, c and d were treated with the indicated OXA dose (μg/mL) of 3.2, 6.4, 12.8 and 25.6, respectively.